-By ArdorComm News Network
March 23, 2024
NVIDIA has unveiled over two dozen new microservices aimed at empowering healthcare enterprises worldwide to leverage the latest advancements in generative AI across drug discovery, medical technology (MedTech), and digital health. These microservices, available on every NVIDIA DGX Cloud, enable healthcare organizations to harness the power of generative AI from any location and on any cloud platform.
The suite of NVIDIA healthcare microservices comprises optimized NVIDIA NIM™ AI models and workflows equipped with industry-standard APIs. These microservices serve as foundational elements for developing and deploying cloud-native applications, offering capabilities in advanced imaging, natural language processing, speech recognition, and digital biology generation, prediction, and simulation.
Moreover, NVIDIA has made available accelerated software development kits and tools, including Parabricks®, MONAI, NeMo™, Riva, and Metropolis, as NVIDIA CUDA-X™ microservices. These tools accelerate healthcare workflows, spanning drug discovery, medical imaging, and genomics analysis.
The deployment of these microservices marks a significant milestone in transforming healthcare, enabling pharmaceutical companies, physicians, and hospitals to capitalize on generative AI for various applications. This includes screening vast libraries of drug compounds, enhancing patient data collection for early disease detection, and implementing intelligent digital assistants.
NVIDIA’s Vice President of Healthcare, Kimberly Powell, highlighted the transformative potential of generative AI in revolutionizing drug discovery, stating, “For the first time in history, we can represent the world of biology and chemistry in a computer, making computer-aided drug discovery possible.”
The suite of healthcare microservices includes NVIDIA NIM, which provides optimized inference for various models across imaging, MedTech, drug discovery, and digital health domains. These models enable generative biology, chemistry, and molecular prediction. Additionally, a collection of models for drug discovery, such as MolMIM for generative chemistry and ESMFold for protein structure prediction, are included.
Various industry leaders and application providers are already leveraging these microservices to advance healthcare. Companies like Amgen and Abridge are utilizing generative AI to enhance drug discovery processes and clinical interactions, respectively, demonstrating the broad impact and potential of these technologies in transforming patient care and medical research.
Developers interested in experimenting with NVIDIA AI microservices can access them at ai.nvidia.com, while production-grade NIM microservices are available through NVIDIA AI Enterprise 5.0. These services can be deployed on NVIDIA-Certified Systems™ and leading public cloud platforms, including Amazon Web Services (AWS), Google Cloud, Microsoft Azure, and Oracle Cloud Infrastructure, as well as on NVIDIA DGX™ Cloud.